These tumor antigen-loaded DCs possess high antigen-presenting efficiency with sufficient exogenous costimulatory signals and can prime CD4+ T cells via peptide-MHC II complexes and CD8+ T cells via peptide-MHC I molecules [98, 99]. The gene discussed is CD4; the disease is neoplasm.